On March 25, 2026, GH Research PLC announced positive results from its Phase 2b trial of mebufotenin (GH001) for treatment-resistant depression, published in JAMA Psychiatry. A related manuscript was also accepted for publication, suggesting a strong outcome for the drug's efficacy regardless of past treatment failures.